Evidence map›Paper›PMID 26098869›Full record

ArticleNature genetics2015

Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.

Erica J Childs, Evelina Mocci, Daniele Campa, Paige M Bracci, Steven Gallinger, Michael Goggins, Donghui Li, Rachel E Neale, Sara H Olson, Ghislaine Scelo and 52 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 172 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
172citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

172 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. HGG advances · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Mutations in the pancreatic secretory enzymesProceedings of the National Academy of Sciences of the United States of America · 2018
    Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

112 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

62 authors.

Erica J ChildsDepartment of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Evelina MocciDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Daniele Campa1] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [2] Department of Biology, University of Pisa, Pisa, Italy.
Paige M BracciDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Steven GallingerLunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
Michael GogginsDepartment of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Donghui LiDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rachel E NealeDepartment of Population Health, QIMR Berghofer Medical Research Institute, Kelvin Grove,Queensland, Australia.
Sara H OlsonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ghislaine SceloInternational Agency for Research on Cancer (IARC), Lyon, France.
Laufey T AmundadottirDivision of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.ORCID 0000000318598971
William R BamletDepartment of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Maarten F BijlsmaLaboratory for Experimental Oncology and Radiobiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Amanda BlackfordDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Michael BorgesDepartment of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Paul BrennanInternational Agency for Research on Cancer (IARC), Lyon, France.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
H Bas Bueno-de-Mesquita1] Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. [2] Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, the Netherlands. [3] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [4] Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Gabriele CapursoDigestive and Liver Disease Unit, 'Sapienza' University of Rome, Rome, Italy.
Giulia M CavestroUniversità Vita Salute San Raffaele and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Kari G ChaffeeDepartment of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.ORCID 0000000273131875
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.
Sean P Cleary1] Department of Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada. [2] Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Michelle Cotterchio1] Cancer Care Ontario, University of Toronto, Toronto, Ontario, Canada. [2] Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Lenka ForetovaDepartment of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and Medical Faculty Masaryk University, Brno, Czech Republic.
Charles Fuchs1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [2] Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Niccola FunelDepartment of Surgery, Unit of Experimental Surgical Pathology, University Hospital of Pisa, Pisa, Italy.
Maria GazouliDepartment of Medical Sciences, Laboratory of Biology, School of Medicine, University of Athens, Athens, Greece.ORCID 0000000232956811
Manal HassanDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Joseph M HermanDepartment of Radiation Oncology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ivana HolcatovaInstitute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
Elizabeth A HollyDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Robert N HooverDivision of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, US Department of Health and Human Services, Bethesda, Maryland, USA.
Rayjean J HungLunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
Vladimir JanoutDepartment of Preventive Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
Timothy J KeyCancer Epidemiology Unit, University of Oxford, Oxford, UK.
Juozas KupcinskasDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.ORCID 0000000287607416
Robert C KurtzDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Stefano LandiDepartment of Biology, Section of Genetics, University of Pisa, Pisa, Italy.
Lingeng LuDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.ORCID 0000000198710809
Ewa Malecka-PanasDepartment of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland.
Andrea MambriniDepartment of Oncology, Azienda USL 1 Massa Carrara, Massa Carrara, Italy.
Beatrice Mohelnikova-DuchonovaLaboratory of Toxicogenomics, Institute of Public Health, Prague, Czech Republic.
John P NeoptolemosNational Institute for Health Research (NIHR) Pancreas Biomedical Research Unit, Liverpool Clinical Trials Unit and Cancer Research UK Clinical Trials Unit, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.ORCID 0000000262017399
Ann L ObergDepartment of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Irene OrlowDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Claudio PasqualiDepartment of Surgery, Gastroenterology and Oncology, University of Padua, Padua, Italy.
Raffaele PezzilliPancreas Unit, Department of Digestive Diseases, Sant'Orsola-Malpighi Hospital, Bologna, Italy.
Cosmeri RizzatoGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Amethyst SaldiaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Aldo ScarpaARC-NET-Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, Italy.
Rachael Z Stolzenberg-SolomonNutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland, USA.
Oliver StrobelDepartment of General Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Francesca TavanoDivision of Gastroenterology and Research Laboratory, IRCCS Scientific Institute and Regional General Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy.
Yogesh K VashistDepartment of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pavel VodickaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Sciences, Prague, Czech Republic.
Brian M Wolpin1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [2] Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Herbert YuEpidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.ORCID 0000000339504815
Gloria M PetersenDepartment of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Harvey A RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
Alison P Klein1] Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. [2] Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
CALIFORNIA COORDINATED CANCER PREVENTION & CONTROL PROGRAMU58DP003862 · DP · CALIFORNIA STATE DEPT OF PUBLIC HEALTH · PI SNIPES, KURT P · 2012 to 2014
$31.5M
Pancreatic Cancer Genetic Epidemiology Consortium (PACGENE)R01CA097075 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2002 to 2012
$15.8M
Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
Whole Genome Scan in the Pancreatic Cancer Cohort Consortium (PanScan)ZIACP010193 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI STOLZENBERG-SOLOMON, RACHAEL · 2009 to 2025
$9.5M
Validation and Fine-Scale Mapping of Pancreatic Cancer Susceptibility Loci (Study)R01CA154823 · NCI · JOHNS HOPKINS UNIVERSITY · PI KLEIN, ALISON P · 2011 to 2020
$5.7M
Prospective Cohort Collaborative in Pancreatic Cancer Epidemiology & PathogenesisR01CA124908 · NCI · DANA-FARBER CANCER INST · PI FUCHS, CHARLES S · 2007 to 2012
$4.3M
Case-Control Study of Pancreas Cancer Etiologic FactorsR01CA098870 · NCI · YALE UNIVERSITY · PI RISCH, HARVEY A · 2003 to 2008
$3.5M
Molecular Epidemiology of Pancreatic CancerR01CA109767 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRACCI, PAIGE M. · 2005 to 2010
$3.2M
Cancer Research UK 15957Cancer Research UK 16491Cancer Research UK 8968Department of Health PB-PG-0407-13363NCATS NIH HHS UL1 TR000371NCCDPHP CDC HHS U58 DP003862NCCDPHP CDC HHS U58 DP003862-01NCI NIH HHS 5R01 CA098870NCI NIH HHS HHSN261201000140CNCI NIH HHS P20 CA102701NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA062924NCI NIH HHS P50 CA102701NCI NIH HHS P50 CA62924NCI NIH HHS R01 CA097075NCI NIH HHS R01 CA098870NCI NIH HHS R01 CA1009767NCI NIH HHS R01 CA109767NCI NIH HHS R01 CA109767-S1NCI NIH HHS R01 CA124908NCI NIH HHS R01 CA154823NCI NIH HHS R01 CA97075NCI NIH HHS R03 CA123546NCI NIH HHS R03 CA123546-02NHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100011IWorld Health Organization 001
6 · The paper itself

Abstract

Pancreatic cancer is the fourth leading cause of cancer death in the developed world. Both inherited high-penetrance mutations in BRCA2 (ref. 2), ATM, PALB2 (ref. 4), BRCA1 (ref. 5), STK11 (ref. 6), CDKN2A and mismatch-repair genes and low-penetrance loci are associated with increased risk. To identify new risk loci, we performed a genome-wide association study on 9,925 pancreatic cancer cases and 11,569 controls, including 4,164 newly genotyped cases and 3,792 controls in 9 studies from North America, Central Europe and Australia. We identified three newly associated regions: 17q25.1 (LINC00673, rs11655237, odds ratio (OR) = 1.26, 95% confidence interval (CI) = 1.19-1.34, P = 1.42 × 10(-14)), 7p13 (SUGCT, rs17688601, OR = 0.88, 95% CI = 0.84-0.92, P = 1.41 × 10(-8)) and 3q29 (TP63, rs9854771, OR = 0.89, 95% CI = 0.85-0.93, P = 2.35 × 10(-8)). We detected significant association at 2p13.3 (ETAA1, rs1486134, OR = 1.14, 95% CI = 1.09-1.19, P = 3.36 × 10(-9)), a region with previous suggestive evidence in Han Chinese. We replicated previously reported associations at 9q34.2 (ABO), 13q22.1 (KLF5), 5p15.33 (TERT and CLPTM1), 13q12.2 (PDX1), 1q32.1 (NR5A2), 7q32.3 (LINC-PINT), 16q23.1 (BCAR1) and 22q12.1 (ZNRF3). Our study identifies new loci associated with pancreatic cancer risk.

Indexed as

Polymorphism, Single NucleotideAgedAustraliaChromosomes, Human, Pair 17Chromosomes, Human, Pair 2Chromosomes, Human, Pair 3Chromosomes, Human, Pair 7EuropeFemaleGene FrequencyGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansMale

Identifiers

PMID26098869
PMCPMC4520746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.